NLX-101 (F15599) is under development for the treatment of Rett syndrome and depression. The drug candidate is administered by oral route. The drug candidate is a new chemical entity (NCE). The drug ...
Mavoglurant is under development for the treatment of cocaine use disorder, alcohol use disorder and for language learning in young children with fragile X syndrome (FXS). The drug candidate is ...
Center for Global Biopharmaceutical Research, Korea Institute of Toxicology, Daejeon 34114, South Korea Human and Environmental Toxicology, University of Science and Technology, Daejeon 34113, South ...